Showing results (2391-2400 of 2,413) with videos related to

Sort By:
Pageof 242
Peerj|September 17, 2016
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapiesPhillip Lord, Rachel Spiering, Juan C Aguillon, et al.
MMWR. Morbidity and Mortality Weekly Report|September 21, 2018
Multidrug-Resistant Campylobacter jejuni Outbreak Linked to Puppy Exposure - United States, 2016-2018Martha P Montgomery, Scott Robertson, Lia Koski, et al.
The Lancet. Oncology|October 1, 2011
Delivering affordable cancer care in high-income countriesRichard Sullivan, Jeffrey Peppercorn, Karol Sikora, et al.
Research and Practice in Thrombosis and Haemostasis|November 17, 2025
Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia AIlja Oomen, Amal Abdi, Linda Broer, et al.
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 4, 2024
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona MeetingJalid Sehouli, Jolijn Boer, Alison H Brand, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona MeetingJalid Sehouli, Jolijn Boer, Alison H Brand, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Pageof 242